Placentex is commonly used to offer supportive therapeutic benefit by acting as a biostimulant, supporting the body's natural processes of tissue repair. PDRN is relevant in conditions involving structural damage, including the clinical management of superficial wounds and skin ulcers. It is used across domains where localized tissue damage or degeneration is the primary issue, assisting in the management of distressing structural and functional manifestations.

---

The medication is commonly used to help manage conditions characterized by impaired tissue integrity, including chronic non-healing wounds and certain diabetic foot ulcers. It is also applied across conditions involving dermal structural degradation, and may assist with symptoms related to aging, such as loss of elasticity, fine lines, and acne scars, and supports tissues during post-procedural recovery. Furthermore, it assists with conditions that present with functional impairment due to soft tissue degeneration, including tendinopathies.

“The use is relevant in situations where symptoms relate to chronic tissue damage and require supportive relief.”

The use is relevant in situations where symptoms create noticeable functional strain or when additional symptomatic support is needed. The benefit provided helps manage conditions where structural repair is needed, which assists with maintaining functional stability and supports general well-being during symptomatic phases.

---

Quick Fact: Support for Chronic Tissue Conditions

Placentex is relevant for managing Wood conditions marked by persistent symptoms related to structural damage, contributing to regenerative processes and helping ease the overall symptom load.

Placentex, which contains human placental extract, is prescribed for conditions related to tissue repair and regeneration. Its uses include the management of chronic non-healing wounds, such as diabetic ulcers and pressure sores, as well as the treatment of pelvic inflammatory disease (PID). The decision to use Placentex should always be made by a qualified healthcare professional who will assess the individual's specific needs and medical history.

---

Who Should NOT Use Placentex?

The primary contraindication for Placentex is a known hypersensitivity or allergy to human placenta extract or any other components of the formulation. To ensure safe use, individuals with certain pre-existing health conditions should use caution and discuss their medical profile with their doctor before starting treatment.

Group	Precautionary Status
Pregnancy/Breastfeeding	Use only if clearly needed and the potential benefits justify the risks, under a doctor’s guidance.
Children	Use is not generally recommended unless specifically advised by a pediatrician or specialist.
Severe Organ Impairment	Caution is advised; use in patients with severe liver or kidney disease is generally not recommended without specialist consultation.

Interactions with other medicines and products

Official regulatory documentation on Placentex (Polydeoxyribonucleotide) defines its interaction profile primarily through pharmacodynamic restrictions and specific pharmacokinetic properties. Information on drug interactions must be consistent with statements issued by government health authorities.

Documented Interaction Patterns

Interaction Type	Interacting Substance/Class	Official Constraint or Outcome
Pharmacodynamic Restriction	Corticosteroids (Systemic or Local) and Systemic Immunosuppressive Agents	Formal restriction against co-administration due to potential interference with the drug’s regenerative and biostimulant activity.
Timing Requirements	Corticosteroids/Immunosuppressives	Administration requires an exclusion or wash-out period (e.g., one month) for these agents prior to use, as noted in regulatory-aligned protocols.
Metabolic Non-Interaction	CYP450 Enzyme System	Documented absence of interaction risk; the drug is not metabolized by the hepatic CYP450 system but is cleared by non-specific plasma DNA nucleases.
Food/Substance Interaction	Food, Alcohol, Herbal Products	No interactions with food, alcohol, or herbal products are explicitly documented in official regulatory summaries.

Official Regulatory Summary

The established regulatory structure emphasizes that the drug is free from known hepatic metabolic interactions due to its clearance pathway, which bypasses the CYP450 enzyme system. The most significant interaction constraint is the necessary exclusion of strong anti-inflammatory and immunosuppressive therapies. This restriction is a mandatory measure to prevent the pharmacodynamic counteraction of Placentex’s intended tissue support effects.

How Placentex Works

The mechanism of Placentex (PDRN) is defined by a dual-action strategy that modulates cellular signaling while providing fundamental biological materials for repair. This strategy focuses on engaging specific molecular targets to modulate pathways associated with tissue restoration.

---

1. Activation of Receptor Signaling and Anti-inflammation

This domain centers on the Adenosine A 2A Receptor ( A 2A AR), which is activated by PDRN's breakdown product, adenosine. Agonism of this receptor modulates key inflammatory pathways (like NF-kappa B), leading to the suppression of excessive pro-inflammatory signals, thereby contributing to the dampening of inflammatory cascade effects.

2. Stimulation of Angiogenesis and Tissue Trophism

A 2A AR activation further triggers the release of Vascular Endothelial Growth Factor (VEGF). This mechanistic cascade drives neovascularization (new blood vessel formation), which increases localized blood flow and nutrient delivery (trophism).

3. Provision of Building Blocks for Cellular Synthesis

This non-receptor mechanism utilizes the Salvage Pathway, where PDRN fragments are directly incorporated by cells (like fibroblasts) into new DNA and RNA strands. This provides the essential nucleotide precursors required for cell proliferation and the synthesis of new structural proteins, facilitating the synthesis and deposition of new extracellular matrix components.

Administration Scope

Placentex (Polydeoxyribonucleotide) administration is characterized by a specific route, dose, and schedule for each available formulation. The drug is available as an injectable solution in two primary strengths: 5.625 mg/3 ml and 2.25 mg/3 ml ampoules, along with topical forms such as a 0.08% cream. The injectable solution is designated for intramuscular (i.m.) or subcutaneous (s.c.) routes, requiring administration under professional supervision. Topical forms, including the cutaneous solution and cream, are intended for local external application, and the ophthalmic solution is administered via instillation into the conjunctival fornix.

---

Standardized Regimen and Cycles

The established dosing regimen for the injectable solution is 1 ampoule per day, irrespective of the chosen strength, for parenteral use. Topical forms are typically applied 1 or 2 times per day, while the eye drops require 2 to 4 instillations per day. The overall course for the injectable form is structured in short, repeatable treatment cycles of 15 - 20 days. The injectable solution is ready-to-use and does not require dilution. No specific dose adjustments are indicated for patient groups such as older adults or those with renal impairment. All use is subject to the prescriber's determination.

Research evidence / Overview of studies for Placentex

Evidence for use in Chronic Non-Healing Wounds and Ulcers

Research involving Polydeoxyribonucleotide (PDRN) for conditions marked by functional limitations like chronic non-healing wounds and skin ulcers included Randomized Controlled Trials (RCTs) and systematic reviews. These studies included adult and older adult populations, frequently involving individuals diagnosed with diabetic foot ulcers. Researchers monitored specific outcomes related to wound closure, such as the time elapsed until reaching primary wound closure endpoints and measured changes in the surface area of the ulcer over defined observation periods.

Evidence for use in Soft Tissue and Joint Conditions

PDRN was studied for its application in conditions where symptoms may vary in intensity, such as chronic tendinopathy and certain joint pains. The research examined these outcomes related to physical discomfort using a combination of RCTs and observational studies. The primary measurements relied on patient-reported outcomes describing perceived discomfort, such as pain scores, and objective assessments of outcomes reflecting daily functioning or activity level.

Evidence for use in Dermal Structure Support

The research exploring PDRN’s role in supporting dermal structure, such as for skin elasticity and certain aesthetic conditions, is primarily based on smaller observational settings evaluating daily-life functioning (case series) and extensive preclinical investigations. These studies included adult populations, with outcomes monitored including skin hydration, elasticity measurements, and assessments of features like wrinkle depth.

Follow-up and Long-Term Research

Research on PDRN typically monitors patient response over defined time intervals, with most major clinical trials focusing on short- to intermediate-term outcomes. For chronic wounds, the primary endpoints are often assessed within 8 to 12 weeks. However, the long-term effects are not fully established concerning the maintenance of functional status or the continued absence of symptoms over years, especially after the study period has concluded.

Areas Where Research Remains Limited

Scientific reviews indicate several areas where the PDRN evidence base requires further development. The evidence quality varies across studies, with findings often being mixed across different research groups, contributing to research uncertainty. The establishment of standardized administration protocols—including the optimal dosage and delivery method—is not fully established and remains a research gap.

Key Studies & References

1. The effects of polydeoxyribonucleotide on wound healing and tissue regeneration: a systematic review of the literature
2. Polydeoxyribonucleotide in the Treatment of Tendon Disorders, from Basic Science to Clinical Practice: A Systematic Review
3. Polydeoxyribonucleotides as Emerging Therapeutics for Skin Diseases: Clinical Applications, Pharmacological Effects, Molecular Mechanisms, and Potential Modes of Action

Common questions about Placentex (FAQ)

Q: Can I use Placentex if I am currently taking any anti-inflammatory medicine?

Official regulatory documents indicate a formal restriction against co-administration with strong corticosteroids (like prednisone) and systemic immunosuppressive agents (medicines that suppress the immune system). This is because these drugs may interfere with Placentex’s regenerative effects. The documentation does not explicitly detail an interaction profile with common, over-the-counter anti-inflammatory medicines such as NSAIDs (e.g., ibuprofen), but it emphasizes the general constraint regarding strong anti-inflammatory therapies.

---

Q: What specific diseases or conditions is Placentex used to treat?

Placentex is generally categorized as a tissue repair stimulator used to support fundamental healing and structural restoration processes. Official clinical studies and regulatory information indicate its use in areas like chronic non-healing wounds (such as diabetic ulcers), certain soft tissue and joint conditions, and specific dermal structure support applications. The decision for its use is always subject to the prescriber's determination.

---

Q: Can children use Placentex?

According to the official prescribing information, use in children is not generally recommended unless specifically advised by a pediatrician or specialist. This caution is advised because there is no or limited data on the drug's safety and efficacy in the pediatric population. Use in the pediatric population is subject to the prescriber's assessment and determination.

---

Q: What common side effects should I watch out for after an injection?

The most Common side effects documented in the official safety profile are related to the site of administration, such as pain, redness (erythema), swelling (edema), stinging, and a burning sensation. Official sources state that these localized reactions are transient, meaning they are typically mild and resolve on their own without the need for medical intervention. If you experience any concerning or persistent reactions, contact a healthcare professional.

---

Q: What is the chemical name and composition of the active ingredient?

The active substance in Placentex is Polydeoxyribonucleotide (PDRN). This is classified as a biostimulant and is a deoxyribonucleic extract of biological origin, reliably obtained from the DNA of specific salmon species. The regulatory information highlights that this substance is processed to be a high-purity, non-immunogenic biopolymer designed for tissue support.

---

Q: Can I drive or operate machinery after receiving a Placentex injection?

Official product labeling, such as the Summary of Product Characteristics (SmPC), does not typically list specific warnings about Placentex affecting your ability to drive or operate machinery. This is because the regulatory documents do not generally report adverse reactions known to impair cognitive or motor skills. Patients are advised to monitor themselves for any changes in alertness or motor skills; if compromised, they should avoid driving or operating machinery.

---

Q: Does Placentex contain any preservatives or latex?

The full list of inactive ingredients, or excipients, in the formulation can be found in the official product documentation (such as Section 6.1 of the SmPC). This is the source for verifying the presence of specific substances like preservatives or latex, which allows patients with known sensitivities to check the exact composition of the medicine.

The storage and disposal instructions for Placentex (Polydeoxyribonucleotide) are based strictly on official regulatory labeling to ensure product stability and integrity.

Official Storage Requirements

Storage Component	Requirement
Temperature	No special storage precautions (e.g., refrigeration) are required.
Protection	Must be protected from light and kept away from heat sources.

Handling and Disposal

The product must be maintained away from heat sources to preserve its stability.

Regarding disposal, unused or expired Placentex must be discarded in accordance with local requirements established for pharmaceutical waste. Patients and healthcare providers are also directed to report any suspected adverse reactions via the applicable national reporting system.